Get the Stockscreener App
0.79
6.36%
-0.0537
After Hours:
.81
0.02
+2.53%
AIM ImmunoTech Inc stock is traded at $0.79, with a volume of 384.41K.
It is down -6.36% in the last 24 hours and down -36.80% over the past month.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
See More
Previous Close:
$0.8437
Open:
$0.8618
24h Volume:
384.41K
Relative Volume:
0.33
Market Cap:
$2.69M
Revenue:
$202.00K
Net Income/Loss:
$-28.96M
P/E Ratio:
-1.3167
EPS:
-0.6
Net Cash Flow:
$-21.85M
1W Performance:
-35.77%
1M Performance:
-36.80%
6M Performance:
-69.93%
1Y Performance:
+430.73%
1-Day Range:
$0.7701
$0.92
1-Week Range:
$0.7653
$1.25
52-Week Range:
$0.0632
$20.33
AIM ImmunoTech Inc Stock (AIM) Company Profile
Name
AIM ImmunoTech Inc
Sector
Industry
Phone
352 448 7797
Address
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.79 | 2.87M | 202.00K | -28.96M | -21.85M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
AIM ImmunoTech Inc Stock (AIM) Latest News
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering - Caledonian Record
AIM offers $1,000 preferred units plus 1,666 stock warrants to holders - Stock Titan
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event - The Manila Times
Pancreatic cancer drug strategy: AIM ImmunoTech CEO in Feb. 19 live webcast - Stock Titan
AIM ImmunoTech at Corporate Connect: Ampligen’s Role in Pancreatic Cancer - Investing.com Canada
AIM: Ampligen demonstrates strong survival and quality of life benefits in late-stage pancreatic cancer - TradingView
AIM ImmunoTech Launches Rights Offering for Common Stock Holders - GuruFocus
Aim Immunotech Announces Commencement Of Rights Offering - TradingView
Cancer drug developer AIM ImmunoTech seeks $12M from shareholders - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
AIM ImmunoTech to Participate in Corporate Connect Webinar - Intellectia AI
AIM ImmunoTech to Participate in the Corporate Connect - GlobeNewswire
Pancreatic cancer focus: AIM ImmunoTech CEO joins Webull live webinar - Stock Titan
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Sahm
AIM ImmunoTech Eyes $12M Funding Boost with Rights Offering - timothysykes.com
AIM ImmunoTech Inc. (AIM) stock: surges as pancreatic cancer trial shows survival breakthrough - parameter.io
AIM ImmunoTech reports year-end positive phase 2 interim progress for Ampligen® (rintatolimod) plus AstraZeneca's Imfinzi® (durvalumab) in pancreatic cancer - marketscreener.com
AIM ImmunoTech reports data in year-end update from Phase 2 trial of Ampligen - TipRanks
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
AIM ImmunoTech (AIM) Announces Positive Phase 2 Trial Results fo - GuruFocus
AIM ImmunoTech’s $12M Rights Offering: Implications and Prospects - StocksToTrade
Why Is AIM ImmunoTech Stock Up Today? - TipRanks
AIM ImmunoTech Rights Offering Targets $12 Million Boost - timothysykes.com
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial | AIM Stock News - Longbridge
AIM ImmunoTech Provides Interim DURIPANC Clinical Progress Update - TipRanks
AIM ImmunoTech Inc Provides Interim Update on DURIPANC Study - TradingView
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer - ChartMill
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year? - Yahoo Finance
AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering - The Manila Times
AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering - GlobeNewswire
AIM ImmunoTech Stock Trading Halted, Pending Material News Release - marketscreener.com
AIM ImmunoTech Adjusts Class E Warrant Terms After Dividend - TipRanks
AIM ImmunoTech Inc Modifies Class E and F Warrants - TradingView
Why AIM ImmunoTech Inc. (HXB) stock gets analyst attentionSupport Zone Identification & The Smart Money Is Buying These Picks - bollywoodhelpline.com
AIM ImmunoTech granted U.S. patent for Ampligen - MSN
AIM ImmunoTech Highlights Ampligen Development Risks and Plans - The Globe and Mail
Trend Recap: How AIM ImmunoTech Inc stock compares with tech leadersDollar Strength & Entry Point Confirmation Signals - Bộ Nội Vụ
AIM ImmunoTech (NYSEAMERICAN:AIM) Upgraded at Zacks Research - Defense World
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
Rate Cut: Is AIM ImmunoTech Inc HXB stock undervalued after correctionMarket Activity Summary & Free Expert Verified Stock Movement Alerts - Bộ Nội Vụ
AIM ImmunoTech Inc.: - MarketScreener
Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
AIM ImmunoTech (NYSEAMERICAN:AIM) Shares to Split on Friday, January 9th - Defense World
AIM ImmunoTech: One Shr for Every 1,000 Shrs or for Every Outstanding Option or Warrant Having a Right to Stk Dividends >AIM - 富途牛牛
AIM ImmunoTech Announces Stock Dividend - The Manila Times
AIM ImmunoTech to give extra shares to investors via stock dividend - Stock Titan
AIM ImmunoTech receives NYSE American notice of delisting and appeal - MSN
Published on: 2025-12-21 18:10:19 - Улправда
Why AIM ImmunoTech Inc. (HXB) stock is a must watch tickerPortfolio Value Report & Stepwise Entry/Exit Trade Alerts - Улправда
How AIM ImmunoTech Inc. (HXB) stock performs during market turbulenceJuly 2025 Recap & Trade Opportunity Analysis Reports - DonanımHaber
AIM ImmunoTech Inc Stock (AIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):